Drug Profile


Alternative Names: ABBV 066; BI-655066

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Developer AbbVie; Boehringer Ingelheim
  • Class Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action Interleukin-23 subunit p19 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Crohn's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Erythrodermic psoriasis; Plaque psoriasis; Pustular psoriasis
  • Phase II Ankylosing spondylitis; Asthma; Crohn's disease; Psoriatic arthritis
  • Phase I Psoriasis

Most Recent Events

  • 26 Oct 2017 Adverse events and efficacy data from the phase III IMMvent trial in Plaque psoriasis released by Abbvie
  • 26 Oct 2017 Adverse events and efficacy data from the phase III ultIMMa-1 and ultIMMa-2 trials in Plaque psoriasis released by Abbvie
  • 22 Sep 2017 Boehringer Ingelheim completes a phase I trial for Plaque psoriasis in Germany (SC) (NCT02772601)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top